Your browser doesn't support javascript.
loading
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.
Walter, R B; Gyurkocza, B; Storer, B E; Godwin, C D; Pagel, J M; Buckley, S A; Sorror, M L; Wood, B L; Storb, R; Appelbaum, F R; Sandmaier, B M.
Affiliation
  • Walter RB; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA [3] Department of Epidemiology, University of Washington, Seattle, WA, USA.
  • Gyurkocza B; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Storer BE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Godwin CD; Department of Medicine, Residency Program, University of Washington, Seattle, WA, USA.
  • Pagel JM; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Buckley SA; Department of Medicine, Residency Program, University of Washington, Seattle, WA, USA.
  • Sorror ML; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Wood BL; Division of Hematopathology, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
  • Storb R; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Appelbaum FR; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Sandmaier BM; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Leukemia ; 29(1): 137-44, 2015 Jan.
Article in En | MEDLINE | ID: mdl-24888275
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Remission Induction / Leukemia, Myeloid, Acute / Neoplasm, Residual / Hematopoietic Stem Cell Transplantation / Transplantation Conditioning Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2015 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Remission Induction / Leukemia, Myeloid, Acute / Neoplasm, Residual / Hematopoietic Stem Cell Transplantation / Transplantation Conditioning Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2015 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido